Novo's Semaglutide Moves 40% of Obese Children Out of Obesity, Landmark Trial Shows

Novo Nordisk announced on September 7, 2026 that its phase 3 STEP Young trial met its primary endpoint, with 40.4 percent of children aged 6 to under 12 who had obesity moving below the obesity threshold after 68 weeks of once-weekly semaglutide combined with lifestyle modification, compared with 0 percent of children on placebo. The result is a landmark for the Danish drugmaker, headquartered in Bagsværd, because it extends the GLP-1 treatment franchise into the youngest group of patients yet studied in a registrational trial.

The announcement positions semaglutide, the active ingredient in the company's Wegovy brand, as a potential option for a pediatric population that has historically had very few pharmaceutical tools. Childhood obesity is notoriously difficult to treat with lifestyle changes alone, and the small number of approved drug options for young children has left doctors with limited choices when diet and exercise are not enough. The STEP Young data suggests that pharmacology, delivered alongside structured lifestyle programs, could change that calculus.

The trial is part of a broader push by Novo Nordisk to study its weight-loss medicine across the age spectrum, and the pediatric readout comes at a time when the GLP-1 class as a whole is being tested in ever younger and more diverse populations. Because the trial enrolled children as young as 6, the safety questions involved are different from those in adult studies, and the company said it monitored growth and pubertal development as part of its assessment.

Key Facts

BioSpace reported on September 7, citing the Novo Nordisk press release, that 40.4 percent of children treated with semaglutide achieved a BMI below the obesity threshold at week 68, while none of the children in the placebo group reached that milestone. The gap between the two arms is the headline result, and it is unusually stark for a pediatric metabolic trial.

BioSpace reported on September 7 that the trial enrolled 165 children aged 6 to under 12, more than 85 percent of whom had severe obesity, defined as class II or class III, at baseline. That detail matters because severe early-onset obesity is the hardest form of the condition to reverse and the population most in need of effective intervention, which means the result was achieved in a group that started from a difficult position.

GlobeNewswire reported on September 7 that the treatment combined once-weekly semaglutide with a reduced-calorie diet and increased physical activity, mirroring the lifestyle modification approach used across the STEP clinical program. All participants received the lifestyle intervention, so the difference between the arms isolates the effect of the drug on top of standard behavioral care.

BioSpace reported on September 7 that the trial monitored growth and pubertal development without raising major safety flags, and that full results are scheduled to be presented at ObesityWeek, the field's main annual meeting, running from November 14 to 17 in Washington, DC. BioSpace reported on September 7 that the outcome extends GLP-1 competition into younger pediatric obesity, an area where approved options remain limited.

Analysis

The bigger picture here is that the GLP-1 drug class, which has already transformed adult obesity care and reshaped entire business models at Novo Nordisk and its rivals, is now systematically moving down the age ladder, and STEP Young is the clearest evidence yet that regulators and drugmakers are preparing for a future in which severe childhood obesity is treated with injectable medicines rather than lifestyle guidance alone. The 40.4 percent result against 0 percent on placebo is the kind of effect size that forces a conversation about access, cost and long-term safety in a population that cannot fully consent for itself.

What this really means is that the trial's success is likely to intensify a debate that has simmered since the first pediatric GLP-1 studies appeared. On one side, clinicians argue that severe obesity in a 7-year-old is a chronic disease with real metabolic consequences, and that withholding an effective drug is not neutral. On the other side, pediatricians and parents worry about giving a lifelong metabolic medicine to children whose brains and bodies are still developing, and about whether children will stay on the drug indefinitely to maintain the effect. The STEP Young safety monitoring of growth and pubertal development is designed to address those worries, but a 68-week trial cannot answer questions that will take decades to resolve.

Historically, pediatric obesity pharmacotherapy has been a graveyard of modest expectations. Before the GLP-1 era, the available drugs were few, the effect sizes were small, and many pediatricians concluded that medication was rarely worth the risk. The contrast with the STEP Young numbers is therefore not just an incremental improvement; it is a different category of result, and it will reshape the risk-benefit calculation that guides treatment decisions for children with severe obesity.

There is also a competitive dimension. Novo Nordisk is not alone in chasing the pediatric market, and the ability to show robust efficacy in children aged 6 to under 12 gives the company a potential first-mover advantage in a segment where rivals are still running their own trials. For Novo, which built its weight-loss franchise on Wegovy, a pediatric label expansion would widen the eligible population considerably and extend the commercial runway of a drug that faces looming patent and pricing pressures in adults.

Why It Matters

Childhood obesity is a global public health problem with consequences that compound over a lifetime, and the pool of approved medical options for young children has been very small. A treatment that moves 40.4 percent of children below the obesity threshold at week 68, with no child in the placebo arm achieving that outcome, offers a degree of efficacy that pediatricians have rarely been able to offer families, and it is likely to change clinical guidelines if the full data holds up.

The result also raises difficult questions about equity and access. GLP-1 medicines are expensive, demand for them is high, and supply has at times been constrained, and those pressures will only grow if the drugs become standard care for children. The children most affected by severe obesity are often those with the least access to specialist care and the fewest resources to afford lifelong treatment, which means the arrival of an effective pediatric drug could widen health disparities even as it helps the families who can reach it.

Finally, the trial is a reminder that the frontier of obesity medicine has moved from adults to adolescents to young children in the span of a few years. That trajectory forces regulators, insurers and parents to decide how comfortable they are with chronic drug use starting at age 6, and it puts the question of long-term safety, including effects on growth, puberty and future metabolic health, at the center of the conversation.

Next Up

The most immediate milestone is ObesityWeek, where the full STEP Young results are scheduled to be presented between November 14 and 17 in Washington, DC. The presentation will give clinicians their first detailed look at the secondary endpoints, including the magnitude of BMI reduction, the effects on weight-related complications, and the safety profile in the subgroup of children with severe obesity.

Beyond the conference, the next major step is regulatory. Novo Nordisk will need to decide whether to file the STEP Young data with the US Food and Drug Administration and other agencies for a pediatric indication, and the outcome of those submissions will determine whether semaglutide actually reaches children aged 6 to under 12 in clinical practice. Watch also for how rivals respond with their own pediatric readouts, since the competitive landscape for childhood obesity treatment is likely to be defined over the next 18 months.

For families and clinicians, the practical question is how the results translate into real-world care, including dosing, monitoring of growth and pubertal development, and the counseling that will be needed to set expectations about a medicine that may need to be continued to maintain its effects. The trial has opened the door; the next phase will be about whether the health system walks through it responsibly.